Yu Liu MD

• A dedicated and enthusiastic attending oncologist with extensive clinical experience in cancer diagnosis and treatment. Specialized in solid tumors, including lung, breast, liver, gastric cancers, and other malignancies.
• Over 8 years of experience in clinical research, encompassing both sponsor-initiated trials (SIT) and investigator-initiated trials (IIT), with a focus on advancing cancer therapies.
• Substantial experience as an editor of a professional oncology information platform and as an external medical consultant for pharmaceutical companies, complemented by involvement in international medical missions.

 Investigator-initiated Trials

• A prospective single-center study: local and systemic cytokine dynamics induced by tace therapy in patients with hepatocellular carcinoma.
• A retrospective single-center study: comparing the prognostic value of response assessment tools and li-rads in hepatocellular carcinoma patients after brachytherapy and chemoembolization.

 Sponsor-initiated Trials

• A randomized, double-blind, placebo-controlled, multi-center phase iii clinical trial: efficacy and safety study of olaparib in combination with paclitaxel to treat advanced gastric cancer. (nct01924533 / sponsored by astrazeneca).
• A randomized double-blind parallel-group multi-center phase iii clinical trial: stress ulcer prophylaxis of intravenous esomeprazole in chinese seriously ill patients (sup). (nct02157376 / sponsored by astrazeneca).
• A randomized, single-blind, multicenter, positive parallel-controlled, non-inferiority clinical trial of recombinant human erythropoietin injection for chemotherapy-induced marrow suppression. (sponsored by 3sbio).

• Schmidt R.,......Yu Liu, etc. Comparing the Prognostic Value of Quantitative Response Assessment Tools and LIRADS Treatment Response Algorithm in Patients with Hepatocellular Carcinoma Following Interstitial High-Dose-Rate Brachytherapy and Conventional Transarterial Chemoembolization. Cancers. 2025 Apr 9;17(8):1275. doi: 10.3390/cancers17081275.
• Poster presentation: Utilizing VSOPs to characterize variations in the pericellular glycocalyx of M1/M2-like macrophages in tumor immune microenvironments. 4th Annual Conference on Global Nanotechnology. Valencia Spain. 2025 Jun.(first author）
• Yu Liu, et al: The role of glycocalyx diversity and thickness for nanoparticle internalization in M1/M2-like macrophages. Nano Letters. 2024 Dec11;24(49): 15607-15614. (first author)
• Oral presentation: Strategies for HCC imaging and therapy based on the characterization of the pericellular glycocalyx on M1/M2 macrophages. 4th Colloquium of the CRC 1340/2 -Matrix in Vision. 2023 Jul. (speaker)
• Shuai Chen, Xiurong Cai, Yu Liu, et al: The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. Bioengineered. 2022 May;13 (5): 11740-11751. (co-first author)
• Shuai Chen, Yu Gong, Yu Liu, et al: INHBA is a novel mediator regulating cellular senescence and immune evasion in colorectal cancer. Journal of Cancer. 2021 Aug 13;12(19): 5938-5949.
• Dong Li, Yu Liu, et al: MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting API-5. FEBS Letters, 589(2015):68–76, ISSN: 1873-3468. (co-first author)
• Yu Liu, et al: Effects of miR-1 on gene expressing of BAG4 in hepatocarcinoma cell line. Immunological journal, 2014, 30(6):479-487, ISSN: 1000-8861. (first author）
• Yu Liu, et al: Mechanisms of recurrence after microwave ablation for liver cancer: insights from ScRNA-seq, proteomics, and metabolomics analyses. Frontiers in Oncology, (under review/first author）
• Emine YY., Yu Liu, et al: Changes in inflammatory cytokines and immune cell profiles in both local and systemic environments during TACE treatment of hepatocellular carcinoma . (Manuscript/co- first author）

• Innovative Talent Research Funding of Good Doctor Pharmaceutical Group (2021)
• First-Class Prize of 1st National GIST target therapy debate (Southwestern China/2019)
• Top Ten Doctors of Chengdu General Hospital of China (2016).
• Outstanding Contribution Reward of Chinese Medical Team against Ebola (2015）.

Medical Licence-Ministry of Health of PR.China